Trial 6G-15-2


An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or IV Gliomas with IDH1 Mutation

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Other
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Frances Chow, M.D.
Other Trial Staff:  Sandy Leong, Coordinator, Anush Arakelyan, Coordinator, Aida Lozada, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.